ARA-290 vs NA-Semax Amidate
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cibinetide, ARA 290
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (EPO), engineered to calm inflammation and repair nerves without thickening the blood the way EPO does. It has been tested in real Phase 2 human trials, mainly for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, and holds FDA orphan drug status, but it was never approved and development largely stalled. So: genuine clinical data, promising signals, no finish line.
Also: N-Acetyl Semax Amidate, NA-Semax
NA-Semax Amidate is the stabilized form of Semax, the Russian nootropic peptide derived from a fragment of ACTH. Same modification logic as the Selank variant: acetyl group at one end, amide at the other, both there to stop enzymes chewing it up before it does anything. It is the most widely used Semax variant in Western nootropic circles, largely on the strength of that stability argument.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | ARA-290 | NA-Semax Amidate |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | EPO does two jobs - it tells bone marrow to make red blood cells, and separately it protects and repairs injured tissue. ARA-290 was designed to trigger only the second job. It selectively activates the innate repair receptor (IRR), a heteroreceptor that pairs the EPO receptor with the CD131 beta-common chain and shows up at sites of injury and inflammation. By switching on this receptor, the peptide dampens inflammatory signaling and reduces cell death while leaving red blood cell production alone, which sidesteps EPO's clotting and cardiovascular risks. Some research also links its pain-relieving effect to modulation of the TRPV1 channel where the immune system and nociception intersect. | Semax is a synthetic analog of ACTH (4-10), a fragment of adrenocorticotropic hormone that has been stripped of hormonal activity while retaining effects on the brain. Its best-characterized action is a marked increase in BDNF and NGF expression in the hippocampus, which is the mechanistic basis for the memory and neuroprotection claims. It also modulates dopaminergic and serotonergic transmission, and affects the melanocortin system, which is thought to contribute to its effects on attention and motivation. Notably it does this without the HPA axis activation you would expect from something derived from ACTH, because the fragment lacks the region responsible for that. The acetylation and amidation slow degradation by peptidases, so more of the dose survives to act. |
| Common Dosing | 4 mg daily Once daily | 300-600 mcg daily (intranasal) Once or twice daily, morning and early afternoon |
| Administration | Subcutaneous injection | Intranasal is the standard and best-supported route, since it was developed as a nasal formulation |
| Typical Duration | 28-day courses in trials | Community protocols commonly report 2-4 week blocks |
| Best Time to Take | Consistent daily timing | Morning, or morning and early afternoon if split |
Possible Side Effects May vary by individual |
|
|
| Research Summary | ARA-290 has more real human data than most peptides in this category. A 2015 phase 2 trial published in Molecular Medicine (Brines et al., registered as NTR3858) found that ARA-290 improved hemoglobin A1c and lipid profile and significantly improved PainDetect neuropathic symptom scores in type 2 diabetes patients, with increased corneal nerve fiber density in those with small fiber neuropathy. In sarcoidosis-associated small fiber neuropathy, controlled studies reported increased corneal nerve fiber area and more regenerating (GAP-43-positive) skin nerve fibers, though in at least one dose-ranging trial pain did not clearly separate from placebo - an honest caveat worth keeping. Tolerability in these small, early-phase studies has been favorable, with no signal of EPO-style blood thickening. That said, the trials are small and early, ARA-290 holds FDA orphan drug status for sarcoidosis neuropathy but is not approved, and the program stalled around 2020. Net: real clinical evidence pointing in a hopeful direction, but not yet proven enough to be a standard treatment. | Semax has a genuine and reasonably large research base, concentrated in Russia, where it is a registered medicine used for ischemic stroke, cognitive impairment and optic nerve disorders. Animal work consistently supports the BDNF and NGF upregulation, and there is human clinical work in stroke recovery. The important caveat is the same as for Selank: this literature is largely Russian, much of it predates modern trial standards, replication in large Western randomized trials has not happened, and neither the FDA nor the EMA has assessed it. For the amidate variant specifically there is no independent published pharmacology comparing it to standard Semax in humans. The stability modification is chemically sound and widely used, and the assumption that it improves real-world effect is reasonable but unproven. |
Frequently Asked Questions: ARA-290 vs NA-Semax Amidate
What is the difference between ARA-290 and NA-Semax Amidate?
ARA-290 is a cognitive peptide that ara-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (epo), engineered to calm inflammation and repair nerves without thickening the blood the way epo does. it has been tested in real phase 2 human trials, mainly for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, and holds fda orphan drug status, but it was never approved and development largely stalled. so: genuine clinical data, promising signals, no finish line. NA-Semax Amidate is a cognitive peptide that na-semax amidate is the stabilized form of semax, the russian nootropic peptide derived from a fragment of acth. same modification logic as the selank variant: acetyl group at one end, amide at the other, both there to stop enzymes chewing it up before it does anything. it is the most widely used semax variant in western nootropic circles, largely on the strength of that stability argument. The main differences lie in their mechanisms of action and clinical applications.
Which is better, ARA-290 or NA-Semax Amidate?
Neither is universally "better" - the choice depends on your specific goals. ARA-290 is typically used for cognitive purposes, while NA-Semax Amidate is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can ARA-290 and NA-Semax Amidate be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using ARA-290 and NA-Semax Amidate together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.